Join MitoAction and Dr. Jan Smeitink, CEO of Khondrion for our our March Expert Series presentation. MELAS spectrum (m.3243A>G) disorders belong to the most frequently encountered group of primary mitochondrial diseases with an unmet medical need for treatment development. Following an introduction of the clinical disease spectrum Dr. Smeitink will discuss the development and state-of-art of Khondrion’s lead product sonlicromanol.
Is Exercise a New Year’s Resolution for People Affected by Mitochondrial Diseases? Learn about how you can most effectively incorporate exercise into your daily...
Are you OVERWHELMED? This time of year, we look forward to the joy, excitement, and fun of the holiday season: Thanksgiving, Hanukkah, Christmas, Kwanzaa,...
Join us for this monthly expert series where we dive into what a genetic counselor is, what they do, how they can help you...